Questions

1. eGFR Calculation and KDIGO Staging:
   $$ > \begin{aligned} > \text{eGFR} &= \frac{k \times \text{Height (cm)}}{\text{Serum Creatinine (mg/dL)}} \\ > &= \frac{0.413 \times 130}{8.3} \\ > &= \mathbf{6.47\text{ mL/min/1.73 m}^2} \quad (\text{Normal: } >90\text{ mL/min/1.73 m}^2) > \end{aligned} > $$
   • KDIGO Acute Kidney Injury Staging: Stage 3 AKI (Serum creatinine $\ge 3.0$ times baseline, or serum creatinine $\ge 4.0\text{ mg/dL}$, or eGFR $<35\text{ mL/min/1.73 m}^2$, or urine output $<0.3\text{ mL/kg/h}$ for $\ge 24\text{ hours}$ or anuria for $\ge 12\text{ hours}$).
2. Pathophysiology of Pigment-Induced Nephropathy (Rhabdomyolysis):
   • Intrarenal vasoconstriction: Myoglobin scavenges endothelial nitrous oxide (NO) and activates renal sympathetic vasoconstriction and endothelin release, producing profound renal cortical and medullary ischemia.
   • Direct tubular cytotoxicity: In an acidic urinary environment ($\text{pH} < 5.6$), myoglobin dissociates into ferrihemate (hematin), catalyzing free-radical lipid peroxidation of proximal tubular cell membranes.
   • Intratubular cast obstruction: Filtered free myoglobin precipitates with Tamm-Horsfall (uromodulin) protein in distal convoluted tubules, creating obstructive pigmented casts worsened by hypovolemia.
3. Emergent Absolute Indications for Renal Replacement Therapy (RRT):
   • Refractory hyperkalemia ($\text{K}^+ > 6.5\text{ mEq/L}$ with electrocardiographic abnormalities resistant to medical therapy).
   • Refractory fluid overload / pulmonary edema unresponsive to loop diuretics.
   • Severe refractory metabolic acidosis ($\text{pH} < 7.15$ or $\text{HCO}_3^- < 10\text{ mEq/L}$).
   • Symptomatic uremia (uremic encephalopathy, pericardial friction rub, or uremic bleeding diathesis) or azotemia with $\text{BUN} > 100\text{--}150\text{ mg/dL}$.
4. Immediate Medical Stabilization of Hyperkalemia:
   • Membrane stabilization: 10% Calcium Gluconate: $0.5\text{ mL/kg}$ ($50\text{ mg/kg}$) IV over 5–10 minutes with continuous ECG monitoring (onset: 1–3 minutes; duration: 30–60 minutes).
   • Intracellular potassium shift:
     • Regular Insulin $0.1\text{ unit/kg}$ IV combined with $25\%\text{ Dextrose } 2\text{ mL/kg}$ ($0.5\text{ g/kg}$) infused over 30 minutes.
     • Nebulized Salbutamol (Albuterol): $2.5\text{ mg}$ (if $<25\text{ kg}$) or $5\text{ mg}$ via nebulizer over 10–15 minutes.
     • Intravenous Sodium Bicarbonate $8.4\%$: $1\text{--}2\text{ mEq/kg}$ slow IV infusion (especially indicated if concurrent metabolic acidosis).
   • Removal from body: Oral/rectal potassium exchange resin (Sodium polystyrene sulfonate $1\text{ g/kg}$ or Calcium polystyrene sulfonate), pending emergent hemodialysis setup.

flowchart TD
    A[Skeletal Muscle Crush Injury] --> B[Rhabdomyolysis & Cell Lysis]
    B --> C[Massive Release of Myoglobin, K+, Phos, CPK]
    C --> D[Systemic Hyperkalemia: Membrane Excitability]
    C --> E[Renal Elimination of Free Myoglobin]
    E --> F[Renal Vasoconstriction: NO Scavenging]
    E --> G[Aciduria: Ferrihemate Generation & Proximal Tubular Necrosis]
    E --> H[Cast Formation with Tamm-Horsfall Protein in Distal Tubules]
    F & G & H --> I[Oliguric Stage 3 Acute Kidney Injury]
    I --> J[Urgent Dialytic / Hemofiltration Therapy]

1. Diagnosis and Differentials:
   • Primary Diagnosis: Acute Post-Streptococcal Glomerulonephritis (APSGN).
   • Differentials with Low Serum C3:
     • Membranoproliferative Glomerulonephritis (MPGN / C3 Glomerulopathy).
     • Systemic Lupus Erythematosus (Lupus Nephritis Class III/IV).
     • Post-infectious non-streptococcal glomerulonephritis (e.g., shunt nephritis, infective endocarditis).
2. Confirmatory Serology and Complement Kinetics:
   • Streptococcal Serology:
     • Elevated or rising Anti-Streptolysin O (ASO) titer ($>200\text{ IU/mL}$, positive in $>80\%$ post-pharyngitis).
     • Anti-DNase B (Deoxyribonuclease B) titer and Anti-hyaluronidase test (crucial marker particularly if skin pyoderma preceded).
   • Complement Kinetics:
     • Serum C3: Markedly reduced ($<30\text{ mg/dL}$) during the acute phase ($>90\%$ cases). It must normalize within 6 to 8 weeks from onset; failure to normalize beyond 8 weeks mandates a percutaneous renal biopsy to exclude MPGN or lupus nephritis.
     • Serum C4: Usually normal or only mildly depressed (reflecting activation of the alternative complement pathway).
3. Calculation of 24-Hour Fluid Restriction:
   $$ > \begin{aligned} > \text{Body Surface Area (BSA)} &= \sqrt{\frac{\text{Height (cm)} \times \text{Weight (kg)}}{3600}} = \sqrt{\frac{115 \times 20}{3600}} = \sqrt{0.638} = \mathbf{0.80\text{ m}^2} \\ > \text{Insensible Water Loss (IWL)} &= 400\text{ mL/m}^2/\text{day} \times 0.80\text{ m}^2 = \mathbf{320\text{ mL/day}} \\ > \text{Daily Fluid Allowance} &= \text{IWL} + \text{Previous Day Urine Output} + \text{Extra-renal losses} \\ > &= 320\text{ mL} + 140\text{ mL} + 0\text{ mL} = \mathbf{460\text{ mL/24 hours}} > \end{aligned} > $$
4. Pharmacotherapy for Fluid Overload and Hypertensive Emergency:
   • Loop Diuretic:
     • Intravenous Furosemide: $2\text{ mg/kg/dose}$ ($40\text{ mg}$) IV slow bolus over 5 minutes; can be repeated every 6–8 hours (maximum $4\text{ mg/kg/dose}$) to induce natriuresis and alleviate pulmonary congestion.
   • Antihypertensive Agents:
     • Intravenous Labetalol: $0.2\text{--}1.0\text{ mg/kg/dose}$ IV slow bolus over 5 minutes or continuous infusion at $0.25\text{--}1.0\text{ mg/kg/hour}$, titrated to reduce blood pressure by no more than $25\%$ over the first 6–8 hours.
     • Alternatively, oral/sublingual Nifedipine ($0.25\text{--}0.5\text{ mg/kg/dose}$) or oral Amlodipine ($0.1\text{--}0.2\text{ mg/kg/day}$ once daily) once the child is stabilized.

1. Primary Diagnosis and Diagnostic Differentiation:
   • Critical Surgical Emergency: Testicular Torsion (Spermatic Cord Torsion).
   • Differential Features:

2. Diagnostic Signs and Interpretation:
   • Cremasteric Reflex: Stroking the ipsilateral inner thigh normally elicits brisk elevation of the testis ($\ge 0.5\text{ cm}$). Absence of the ipsilateral cremasteric reflex has a $>95\%$ sensitivity for testicular torsion.
   • Prehn Sign: Manual elevation of the affected hemiscrotum over the pubic symphysis. Relief of pain is considered a positive Prehn sign (indicative of epididymitis), whereas lack of relief or exacerbation of pain indicates a negative Prehn sign (strongly indicative of testicular torsion). Note: Prehn sign is unreliable in children and cannot replace imaging or surgical exploration.
3. Ischemic Window and Manual Detorsion Maneuver:
   • Time Window: Optimal testicular salvage rate is $>90\%$ if detorted within 6 hours of pain onset. Viability precipitously drops to $<50\%$ at 12 hours and $<10\%$ after 24 hours.
   • "Open-Book" Manual Detorsion:
     • Most spermatic cord torsions rotate inwards (medially) by 180° to 720°.
     • The physician stands at the supine patient's feet and rotates the affected left testis from medial to lateral (similar to opening the pages of a book: clockwise for the right testis, counter-clockwise for the left testis).
     • Successful detorsion is marked by immediate relief of pain, lowering of the testis into normal vertical lie, and return of Doppler flow; emergent surgical fixation is still mandatory.
4. Definitive Diagnostic Modality and Surgical Protocol:
   • Imaging: High-resolution Color Doppler Ultrasonography (CDUS) of the scrotum (evaluates resistive index, absence or marked diminution of intratesticular parenchymal arterial blood flow, and demonstrates the pathognomonic "whirlpool sign" of the twisted spermatic cord).
   • Urgent Surgical Exploration:
     • Scrotal exploration through a mid-raphe or transverse scrotal incision.
     • Detorsion and wrapping of the affected testis in warm, saline-soaked gauze for 10–15 minutes while administering 100% supplemental oxygen to assess viability.
     • Three-point fixation orchidopexy of the viable testis using non-absorbable sutures (e.g., 3-0/4-0 polypropylene) placed through the tunica albuginea to the dartos fascia.
     • Mandatory prophylactic contralateral orchidopexy during the same sitting due to the bilateral anatomical predisposition ("bell-clapper" deformity). If the affected testis is frankly necrotic/non-viable, orchiectomy is performed.

1. Diagnosis, Inheritance, and Molecular Genetics:
   • Diagnosis: Alport Syndrome (Hereditary Nephritis).
   • Most Common Mode of Inheritance: X-linked Alport Syndrome (XLAS) (accounts for $\approx 80\text{--}85\%$ of all cases).
   • Gene and Defective Collagen Chains:
     • Mutation in the COL4A5 gene located on chromosome Xq22.3.
     • Encodes the $\alpha-5$ chain of Type IV collagen ($\alpha 5[\text{IV}]$), which leads to complete absence or instability of the mature $\alpha 3\cdot\alpha 4\cdot\alpha 5(\text{IV})$ heterotrimer network in the glomerular basement membrane (GBM), cochlea, and ocular basement membranes.
2. Ocular and Audiological Manifestations:
   • Ophthalmological Findings (Pathognomonic):
     • Anterior Lenticonus: Conical protrusion of the anterior lens capsule and cortex into the anterior chamber (virtually pathognomonic).
     • Perimacular yellowish-white flecks (retinopathy sparing the foveola) or dot-and-fleck retinopathy.
     • Posterior polymorphous corneal dystrophy.
   • Audiological Findings:
     • Bilateral, symmetrical, progressive high-frequency sensorineural hearing loss (SNHL) (typically involving frequencies $2000\text{--}8000\text{ Hz}$ on Pure Tone Audiometry; spares conversational frequencies during early childhood).
3. Transmission Electron Microscopy (TEM) Features:
   • Irregular thickening and thinning of the Glomerular Basement Membrane (GBM).
   • "Basket-weave" appearance: Longitudinal splitting, fraying, and multi-lamellation of the lamina densa surrounding electron-dense granulations.
   • Extensive foot-process effacement of overlying podocytes.
4. Pharmacological Renoprotection Strategy:
   • Angiotensin-Converting Enzyme Inhibitors (ACEi): First-line standard of care initiated at the time of persistent microalbuminuria/proteinuria (or even isolated hematuria in boys with XLAS harboring truncating mutations).
     • Enalapril: Starting dose $0.1\text{ mg/kg/day}$ orally once daily; uptitrated every 4–8 weeks to a maximum target dose of $0.5\text{ mg/kg/day}$ (max $20\text{--}40\text{ mg/day}$) or until maximal anti-proteinuric effect is achieved without symptomatic hypotension.
     • Alternatively, Ramipril ($2\text{--}6\text{ mg/m}^2/\text{day}$).
   • Angiotensin Receptor Blockers (ARBs): Used as an alternative (e.g., Losartan $0.7\text{--}1.4\text{ mg/kg/day}$) if dry cough develops from ACE inhibitors.
   • Treatment Target: Reduce urinary protein-to-creatinine ratio (UPCR) by $>50\%$ and maintain blood pressure $<50\text{th percentile}$ for age, sex, and height to delay the onset of ESKD by several decades.

1. Nocturnal Blood Pressure Dipping and Clinical Implications:
   • Normal Dipping Pattern: A physiological decline of $\ge 10\%$ to $20\%$ in both mean systolic and mean diastolic blood pressure during the nighttime (sleep) period compared to the daytime (wake) period:
     $$\text{Dipping Percentage} = \frac{\text{Mean Daytime BP} - \text{Mean Nighttime BP}}{\text{Mean Daytime BP}} \times 100$$
   • **Non-Dipping Profile

1. Most Likely Diagnosis:
   • Autosomal Recessive Polycystic Kidney Disease (ARPKD).
2. Genetic Etiology:
   • Gene: PKHD1 (Polycystic Kidney and Hepatic Disease 1).
   • Chromosomal Localization: Chromosome 6p12.3–p12.2.
   • Encoded Protein: Fibrocystin (also known as Polyductin), localized to the primary cilia and basal body of renal tubular cells and biliary cholangiocytes.
3. Hepatobiliary Lesion and Complications:
   • Characteristic Lesion: Congenital hepatic fibrosis (ductal plate malformation of the intrahepatic bile ducts with periportal fibrosis; associated with Caroli disease / non-obstructive cystic dilatation of intrahepatic bile ducts).
   • Major Clinical Complications:
     • Portal hypertension leading to splenomegaly, hypersplenism (thrombocytopenia, leukopenia), and bleeding gastroesophageal varices.
     • Recurrent ascending bacterial cholangitis.
4. Management Strategy:
   • Blood Pressure Control: Aggressive control of hypertension (target BP <50th percentile) using Angiotensin-Converting Enzyme (ACE) inhibitors (e.g., Enalapril 0.1–0.5 mg/kg/day orally in 1–2 divided doses) or Angiotensin Receptor Blockers (ARBs).
   • Renal Monitoring & Support: Serial monitoring of renal function, electrolytes, and acid-base balance; treatment of progressive chronic kidney disease (phosphate binders, active vitamin D, erythropoietin) and renal replacement therapy (dialysis or preemptive renal transplantation) upon progression to end-stage kidney disease (ESKD).
   • Hepatosplenomegaly & Portal Hypertension Surveillance: Upper gastrointestinal endoscopy surveillance for varices; endoscopic variceal band ligation (EVL) or beta-blocker prophylaxis (propranolol 1–2 mg/kg/day) for variceal bleeding; transjugular intrahepatic portosystemic shunt (TIPS) or surgical portosystemic shunts for refractory bleeding.
   • Infection Management: Prompt broad-spectrum intravenous antibiotic therapy for ascending cholangitis (e.g., ceftriaxone plus metronidazole).
   • Definitive / Advanced Care: Combined liver-kidney transplantation (CLKT) in children with concurrent ESKD and severe hepatic fibrosis/recurrent cholangitis.

1. Acid-Base Interpretation:
   • Primary Disorder: Uncompensated or partially compensated severe metabolic alkalosis with significant hypokalemia and hypochloremia.
   • Physiological Compensation: Hypoventilation to retain carbon dioxide ($\text{pCO}_2$ rises by approximately 0.5–0.7 mmHg for every 1 mEq/L increase in serum $\text{HCO}_3^-$).
2. Differential Diagnosis (Hypokalemic Metabolic Alkalosis with Normal/Low Blood Pressure):
   • Bartter syndrome (Types I–IV).
   • Gitelman syndrome (typically presents later in childhood, associated with hypocalciuria and hypomagnesemia).
   • Chronic surreptitious loop or thiazide diuretic administration.
   • Upper gastrointestinal losses (hypertrophic pyloric stenosis, recurrent vomiting, nasogastric suction).
   • Cystic fibrosis (pseudo-Bartter syndrome secondary to excessive cutaneous salt loss).
   • Congenital chloride diarrhea (presents with high fecal chloride).
3. Definitive Diagnosis and Pathophysiology:
   • Diagnosis: Antenatal/Neonatal Bartter syndrome (Type I or Type II).
   • Molecular Defect: Defect in the thick ascending limb (TAL) of the loop of Henle involving the $\text{Na}^+\text{-K}^+\text{-2Cl}^-$ cotransporter (NKCC2 encoded by SLC12A1, Type I) or the apical renal outer medullary potassium channel (ROMK encoded by KCNJ1, Type II); other types include CLCNKB (Type III, classic), BSND (Type IV with sensorineural deafness), and CASR / MAGED2 (Types V / transient).
4. Pharmacological Management Protocol:
   • Prostaglandin Inhibition:
     • Indomethacin: 1.5–3.0 mg/kg/day orally divided into 2–3 doses (or Celecoxib 2–4 mg/kg/day in older children) to counteract hyper-reninemic hyperaldosteronism driven by elevated renal prostaglandin $\text{PGE}_2$.
     • Concurrent gastroprotection with a proton pump inhibitor (e.g., Omeprazole 1 mg/kg/day).
   • Potassium Supplementation:
     • Potassium chloride ($\text{KCl}$) oral solution: 5–10 mEq/kg/day orally divided into 4–6 doses, titrated to achieve serum potassium >3.0 mEq/L.
   • Sodium and Volume Replacement:
     • Sodium chloride ($\text{NaCl}$) supplementation: 5–10 mEq/kg/day orally in divided doses to replace urinary salt wasting.
   • Potassium-Sparing Diuretics (Adjunctive):
     • Spironolactone: 1–3 mg/kg/day orally in 2 divided doses or Amiloride 0.2–0.4 mg/kg/day orally if hypokalemia is refractory.

1. Comprehensive Diagnosis:
   • Bladder and Bowel Dysfunction (BBD) (previously Dysfunctional Elimination Syndrome) complicated by Recurrent Lower Urinary Tract Infection (UTI).
2. Expected Bladder Capacity (EBC) Calculation:
   $$ > \begin{aligned} > \text{EBC (mL)} &= (\text{Age in years} + 1) \times 30 \\ > &= (11 + 1) \times 30 \\ > &= 12 \times 30 = \mathbf{360\text{ mL}} > \end{aligned} > $$
   (Alternative formula: $\text{EBC} = [\text{Age} \times 30] + 30 = 360\text{ mL}$)
3. Diagnostic Workup:
   • Renal and Bladder Ultrasound (RBUS): Assess for hydronephrosis, renal parenchymal scarring, bladder wall thickening (>3 mm distended, >5 mm empty), post-void residual urine volume (PVR >10% of EBC indicates incomplete emptying), and rectal diameter (>30 mm indicates rectal impaction).
   • Voiding Cystourethrogram (VCUG / MCU): Indicated if ultrasound shows renal scarring or hydroureteronephrosis to rule out Vesicoureteral Reflux (VUR).
   • Dimercaptosuccinic Acid (DMSA) Renal Scintigraphy: Indicated if recurrent febrile UTIs occur to assess renal cortical scarring.
   • Uroflowmetry with Electromyography (EMG): Assesses flow curve (staccato or interrupted pattern) and dyssynergia of the pelvic floor muscles.
   • Voiding and Stooling Diary: 48-hour bladder diary (frequency, voided volumes, leakage episodes, fluid intake) and Bristol Stool Chart.
4. Therapeutic Management Plan:
   • Bowel Management (Primary Priority):
     • Disimpaction if required, followed by maintenance osmotic laxative: Polyethylene glycol (PEG 3350) at 0.5–1.0 g/kg/day orally (titrated to achieve 1 soft, painless Bristol type 3–4 stool daily).
     • High dietary fiber (Age + 5 = 16 g/day) and adequate hydration (1.5–2 liters/day).
   • Standard Urotherapy (Behavioral Modification):
     • Timed scheduled voiding every 2 to 3 hours while awake (regardless of sensation).
     • Proper toilet posture: Feet supported on a footstool, knees apart, leaning slightly forward to relax pelvic floor.
     • Double voiding technique: Voiding, waiting 30–60 seconds, and voiding again to minimize post-void residual urine.
     • Avoidance of holding maneuvers (Vincent curtsy).
   • Antimicrobial Prophylaxis:
     • Initiate daily low-dose uroprophylaxis while correcting BBD: Nitrofurantoin 1–2 mg/kg orally once nightly (or Co-trimoxazole 2 mg/kg trimethoprim component once nightly) for 3–6 months.

1. eGFR Calculation and CKD Staging:
   $$ > \begin{aligned} > \text{eGFR} &= \frac{k \times \text{Height (cm)}}{\text{Serum Creatinine (mg/dL)}} \\ > &= \frac{0.413 \times 114}{2.8} \\ > &= \frac{47.082}{2.8} = \mathbf{16.8\text{ mL/min/1.73 m}^2} > \end{aligned} > $$
   • KDIGO CKD Staging: CKD Stage 4 (Severe reduction in GFR: 15–29 mL/min/1.73 $\text{m}^2$).
2. Radiographic Findings:
   • Metaphyseal cupping, fraying, and splaying of the distal radius and ulna.
   • Widening of the growth plate (physis).
   • Subperiosteal cortical bone resorption (pathognomonic of osteitis fibrosa cystica/hyperparathyroidism), prominently visible along the radial aspect of the phalanges and distal metaphyses.
   • Diffuse osteopenia and osteomalacia/rickets changes (Renal Osteodystrophy).
3. Pathophysiology of Secondary Hyperparathyroidism:
   • Reduced functional nephron mass $\rightarrow$ decreased renal excretion of phosphate $\rightarrow$ hyperphosphatemia.
   • Hyperphosphatemia directly stimulates parathyroid gland PTH secretion and increases Fibroblast Growth Factor 23 (FGF-23) secretion from osteocytes.
   • Decreased renal 1-$\alpha$-hydroxylase enzyme activity (due to parenchymal loss and FGF-23 inhibition) $\rightarrow$ impaired conversion of 25-OH Vitamin D to active 1,25-dihydroxyvitamin D ($1,25(\text{OH})_2\text{D}_3$ / Calcitriol).
   • Low calcitriol levels cause decreased intestinal calcium absorption $\rightarrow$ hypocalcemia.
   • Hypocalcemia, hyperphosphatemia, and lack of vitamin D receptor (VDR) activation trigger chronic parathyroid hyperplasia and excessive PTH synthesis/secretion.
4. Therapeutic Protocol:
   • CKD-Mineral and Bone Disorder (CKD-MBD):
     • Dietary phosphorus restriction (800–1000 mg/day).
     • Non-calcium or calcium-based phosphate binders: Calcium acetate (50–100 mg/kg/day orally in divided doses with meals) or Sevelamer carbonate (400–800 mg orally 3 times daily with meals) to lower serum phosphorus toward age-appropriate targets.
     • Active Vitamin D analog: Calcitriol 0.25 mcg orally once daily or every other day (or active oral pulse therapy), titrated to maintain iPTH between 2–3 times the upper limit of normal for Stage 4 CKD (approx. 70–140 pg/mL) while avoiding hypercalcemia.
   • Metabolic Acidosis:
     • Sodium bicarbonate tablets or oral solution: 1–3 mEq/kg/day orally in 2–3 divided doses to maintain serum bicarbonate $\ge 22\text{ mEq/L}$.
   • Renal Anemia:
     • Iron supplementation: Oral elemental iron 2–3 mg/kg/day or IV iron sucrose if transferring saturation $<20\%$ and ferritin $<100\text{ ng/mL}$.
     • Erythropoiesis-Stimulating Agent (ESA): Recombinant human erythropoietin (rHuEPO) at 50–100 IU/kg/dose subcutaneously 1 to 2 times weekly, titrated to maintain target hemoglobin between 10.0 and 11.5 g/dL.

1. Clinical Diagnosis & Definition:
   • Diagnosis: Congenital Nephrotic Syndrome (CNS).
   • Definition: Onset of heavy nephrotic-range proteinuria, profound hypoalbuminemia, and generalized edema presenting at birth or within the first 3 months (90 days) of life.
2. Genetic Etiologies:
   • NPHS1 (Chromosome 19q13.1): Encodes Nephrin (causes Finnish-type Congenital Nephrotic Syndrome).
   • NPHS2 (Chromosome 1q25–q31): Encodes Podocin (causes steroid-resistant nephrotic syndrome / early-onset focal segmental glomerulosclerosis).
   • WT1 (Chromosome 11p13): Encodes Wilms Tumor 1 protein (causes Denys-Drash syndrome and Frasier syndrome).
   • LAMB2 (Chromosome 3p21): Encodes Laminin $\beta_2$ (causes Pierson syndrome with microcoria).
   • (Alternative valid genes: PLCE1 [Phospholipase C epsilon 1], NUP107, MAGI2).
3. Secondary (Infectious) Etiologies:
   • Congenital Syphilis (Treponema pallidum).
   • Congenital Cytomegalovirus (CMV) infection.
   • Congenital Toxoplasmosis (Toxoplasma gondii).
   • Congenital Rubella, HIV, or Hepatitis B/C.
4. Management Protocol:
   • Albumin Infusions and Diuresis:
     • 20% Salt-Poor Albumin at 1 g/kg (5 mL/kg) IV infused over 2–4 hours, followed by Furosemide 1–2 mg/kg IV mid- or post-infusion, given once or twice daily to maintain serum albumin >1.5–2.0 g/dL and manage third-spacing.
   • Nutrition & Caloric Support:
     • High-calorie (130–150 kcal/kg/day) and high-protein (3.5–4.5 g/kg/day) diet using specialized infant formula or fortified breast milk to compensate for massive urinary protein wasting.
   • Endocrine Supplementation:
     • Levothyroxine (L-thyroxine) 5–10 mcg/kg/day orally to treat secondary hypothyroidism caused by urinary loss of thyroxine-binding globulin (TBG).
   • Thromboprophylaxis:
     • Subcutaneous Low-Molecular-Weight Heparin (Enoxaparin 1.5 mg/kg/dose q12h) or Aspirin (2–5 mg/kg/day) to prevent thromboembolism arising from urinary loss of antithrombin III and thrombocytosis.
   • Antiproteinuric Therapy:
     • ACE inhibitors (Enalapril 0.1–0.3 mg/kg/day) combined with Indomethacin (1–3 mg/kg/day) after renal function stabilizes to reduce glomerular hyperfiltration and proteinuria.
   • Infection Prophylaxis:
     • Penicillin V or Co-trimoxazole prophylaxis, routine pneumococcal/varicella immunization, and prompt broad-spectrum parenteral antibiotics for suspected sepsis.
   • Definitive / Surgical Management:
     • Unilateral or bilateral nephrectomy (medical or surgical) with initiation of peritoneal dialysis when infant reaches 7–9 kg, followed by renal transplantation when weight reaches 10–12 kg.

1. Investigation:
   • Direct Radionuclide Cystography (DRCG) using $^{99\text{m}}\text{Tc}$-pertechnetate or $^{99\text{m}}\text{Tc}$-sulfur colloid instilled through a transurethral urinary catheter.
2. Diagnosis:
   • Right-sided Vesicoureteral Reflux (VUR) - Grade III (moderate reflux into the right ureter and renal pelvis with pelvicalyceal dilatation).
3. Advantages over Fluoroscopic MCU:
   • Dramatically Lower Radiation Dose: Up to 50- to 100-fold lower gonadal radiation exposure compared to conventional fluoroscopic MCU ($\approx 1-5\text{ mrad}$ vs. $100-500\text{ mrad}$).
   • Continuous Dynamic Monitoring: Enables continuous imaging throughout the entire filling, storage, and voiding phases, providing higher sensitivity for detecting transient, low-volume, or intermittent reflux.
4. Limitations:
   • Poor Anatomical Resolution: Incapable of delineating fine anatomical details such as posterior urethral valves, urethral strictures, bladder diverticula, or precise calyceal fornix blunting.
   • Imprecise Reflux Grading: Cannot formally categorize reflux into the standard 5-grade International Reflux Study (IRS) system due to low spatial resolution; typically classified into mild, moderate, or severe only.

graph TD
    A[Child with Recurrent Febrile UTI] --> B[Renal Bladder Ultrasound]
    B --> C{First Investigation for Anatomy & Reflux?}
    C -->|Male or Suspected Lower Tract Anomaly| D[Fluoroscopic MCU: Evaluates Urethra / PUV]
    C -->|Female or Follow-up Surveillance of Known VUR| E[Direct Radionuclide Cystography: Low Radiation]
    E --> F{Reflux Resolved on DRCG?}
    F -->|Yes| G[Discontinue Prophylaxis & Monitor]
    F -->|No / Breakthrough UTI| H[Consider Endoscopic / Surgical Correction]

1. Investigation:
   • $^{99\text{m}}\text{Tc}$-Mercaptoacetyltriglycine ($^{99\text{m}}\text{Tc}$-MAG3) Diuretic Dynamic Renogram (Furosemide / Diuresis Renogram, $F+20$ protocol).
2. Interpretation & Functional Diagnosis:
   • Right Kidney: Normal vascular transit, prompt tracer uptake, and rapid clearance.
   • Left Kidney: Normal or mildly prolonged parenchymal uptake, but progressive tracer accumulation within the dilated pelvicalyceal system with a rising/plateaued curve that shows no washout following furosemide administration.
   • Diagnosis: Significant left Pelvi-Ureteric Junction Obstruction (PUJO) / mechanical outflow tract obstruction.
3. Quantitative Parameters for Obstruction:
   • Diuretic Half-Clearance Time ($T_{1/2}$): Time required for half of the peak radioactivity to clear following furosemide injection:
     • $T_{1/2} < 10\text{ minutes}$: Normal / non-obstructed.
     • $T_{1/2} = 10-20\text{ minutes}$: Equivocal / indeterminate.
     • $T_{1/2} > 20\text{ minutes}$: Diagnostic of mechanical obstruction.
   • Percentage Tracer Washout at 20 Minutes: Post-furosemide clearance $<50\%$ of peak activity at 20 minutes denotes true obstruction.
4. Surgical Threshold:
   • Differential Renal Function (DRF) of the affected kidney $<40\%$, or a documented progressive decline in DRF $>5-10\%$ on sequential follow-up scans.

1. Fractional Excretion of Sodium Calculation:
   $$ > \begin{aligned} > \text{Fe}_{\text{Na}} (\%) &= \left( \frac{\text{U}_{\text{Na}} \times \text{S}_{\text{Cr}}}{\text{S}_{\text{Na}} \times \text{U}_{\text{Cr}}} \right) \times 100 \\ > &= \left( \frac{10\text{ mEq/L} \times 1.0\text{ mg/dL}}{135\text{ mEq/L} \times 90\text{ mg/dL}} \right) \times 100 \\ > &= \left( \frac{10}{12,150} \right) \times 100 \\ > &= \mathbf{0.082\%} \quad (\approx \mathbf{0.08\%}) > \end{aligned} > $$
2. Clinical Interpretation:
   • The calculated $\text{Fe}_{\text{Na}} = 0.082\%$ is markedly $<1\%$.
   • This indicates intact tubular reabsorptive function and avid sodium conservation, confirming Prerenal Acute Kidney Injury (Prerenal Azotemia) rather than intrinsic Acute Tubular Necrosis (where $\text{Fe}_{\text{Na}} > 2\%$).
3. Effect of Diuretics & Alternative Marker:
   • Loop diuretics inhibit the $\text{Na}^+\text{-K}^+\text{-}2\text{Cl}^-$ cotransporter in the thick ascending limb of Henle, causing drug-induced natriuresis that elevates $\text{Fe}_{\text{Na}} > 1\%$ despite prerenal hypovolemia.
   • Alternative Index: Fractional Excretion of Urea ($\text{Fe}_{\text{Urea}}$). A value $<35\%$ confirms prerenal azotemia because urea reabsorption in the proximal tubule is unaffected by loop diuretics.
4. Preterm Neonate Cut-off:
   • In preterm infants $<32$ weeks of gestation, physiological tubular immaturity results in baseline $\text{Fe}_{\text{Na}}$ values between $1\%$ and $3\%$.
   • An $\text{Fe}_{\text{Na}} > 2.5\%$ to $>3\%$ is required to establish the diagnosis of intrinsic ATN in this subgroup.

1. Diagnosis & Inheritance:
   • Diagnosis: Gitelman syndrome (hypokalemic, hypomagnesemic metabolic alkalosis with normal blood pressure).
   • Mode of Inheritance: Autosomal Recessive.
2. Differentiating Investigation:
   • Investigation: 24-hour urinary calcium excretion or spot urinary calcium-to-creatinine ratio ($\text{U}_{\text{Ca}}/\text{U}_{\text{Cr}}$).
   • Expected Finding: Marked Hypocalciuria (spot $\text{U}_{\text{Ca}}/\text{U}_{\text{Cr}} < 0.1\text{ mg/mg}$ or 24-hour urinary calcium $<2\text{ mg/kg/day}$).
   • Contrast with Bartter syndrome, which features normocalciuria or severe hypercalciuria ($\text{U}_{\text{Ca}}/\text{U}_{\text{Cr}} > 0.2\text{ mg/mg}$) with medullary nephrocalcinosis.
3. Defective Transporter & Gene:
   • Transporter: Thiazide-sensitive Sodium-Chloride Cotransporter (NCC / NCCT) in the distal convoluted tubule (DCT).
   • Gene: SLC12A3 (Solute Carrier Family 12 Member 3) on chromosome 16q13.
4. Pharmacological Management:
   • Magnesium Supplementation:
     • Oral Magnesium Chloride, Magnesium Aspartate, or Magnesium Oxide at $4-5\text{ mg elemental Mg/kg/day}$ ($0.2\text{ mmol/kg/day}$) administered in 3 to 4 divided doses with meals (titrated to bowel tolerance).
   • Potassium Supplementation:
     • Oral Potassium Chloride (KCl) at $2-4\text{ mEq/kg/day}$ in 3 to 4 divided doses.
   • Potassium/Magnesium-Sparing Diuretics:
     • Spironolactone: $1-3\text{ mg/kg/day}$ PO divided q12h; or
     • Amiloride: $0.2-0.4\text{ mg/kg/day}$ PO divided q12-24h (blocks ENaC in the collecting duct to decrease potassium and magnesium wasting).

1. Histological Matching:
   • A $\rightarrow$ 3: Rapidly Progressive Glomerulonephritis (RPGN) / Crescentic Glomerulonephritis.
   • B $\rightarrow$ 1: Alport syndrome.
   • C $\rightarrow$ 2: Post-Streptococcal Glomerulonephritis (PSGN).
   • D $\rightarrow$ 4: IgA Nephropathy (Berger disease).
2. Glomerular Crescent Characteristics:
   • Constituents: Proliferation of parietal epithelial cells lining

1. Diagnosis and Autoantigen:
   • Diagnosis: Anti-Glomerular Basement Membrane (Anti-GBM) disease / Goodpasture syndrome with diffuse alveolar hemorrhage.
   • Target Autoantigen: Non-collagenous 1 (NC1) domain of the $\alpha_3$ chain of type IV collagen [$\alpha_3(\text{IV})\text{NC1}$].
2. Renal Biopsy Findings:
   • Direct Immunofluorescence (DIF): Diffuse, smooth, ribbon-like continuous linear deposition of IgG (predominantly IgG1 and IgG3) $\pm$ C3 along the glomerular capillary basement membrane.
   • Light Microscopy: Extensive necrotizing, crescentic glomerulonephritis with cellular crescents typically involving >50% of glomeruli (rapidly progressive crescentic pattern) with glomerular tuft necrosis.
3. Induction Therapy Components:
   • High-dose corticosteroid pulses (Intravenous Methylprednisolone).
   • Cytotoxic immunosuppressive therapy (Cyclophosphamide).
   • Therapeutic Plasma Exchange (Plasmapheresis).
4. Therapeutic Plasma Exchange Protocol:
   • Volume: 4 L exchange per session or 60 mL/kg per session.
   • Replacement Fluid: 5% Human Albumin solution (substitute with Fresh Frozen Plasma [FFP] at 300–600 mL at the end of exchange if active pulmonary hemorrhage is present or within 48–72 hours of a percutaneous renal biopsy to prevent coagulopathy).
   • Frequency & Duration: Daily or alternate-day exchanges for 14 consecutive days (or until circulating anti-GBM antibody titers become undetectable and active hemoptysis completely resolves).

graph TD
    A[Patient: Hemoptysis + Acute Nephritic Syndrome] --> B{Normal C3/C4 & Linear IgG on DIF?}
    B -- Yes --> C[Anti-GBM Disease / Goodpasture Syndrome]
    C --> D[Emergency Triple Therapy]
    D --> E[IV Methylprednisolone 15-30 mg/kg/day x 3 doses]
    D --> F[Oral/IV Cyclophosphamide 2 mg/kg/day]
    D --> G[Plasmapheresis: 60 mL/kg daily x 14 days]
    G --> H[Monitor Anti-GBM Titers until negative]

Prompt initiation of therapeutic plasma exchange combined with cyclophosphamide and corticosteroids is critical; renal recovery correlates inversely with serum creatinine at presentation and the percentage of circumferential crescents on histology. Renal function rarely recovers if the patient is already dialysis-dependent with 100% crescents at presentation unless pulmonary hemorrhage necessitates urgent treatment.

1. Peripheral Smear Finding & Diagnosis:
   • Smear finding: Schistocytes / helmet cells / fragmented erythrocytes and microspherocytes indicating microangiopathic hemolytic anemia (MAHA).
   • Diagnosis: Shiga Toxin-producing Escherichia coli (STEC)-associated Hemolytic Uremic Syndrome (D+ HUS / Post-diarrheal typical HUS).
2. Pathophysiological Mechanism:
   • Shiga toxin (Stx-1 / Stx-2) translocates across damaged colonic epithelium into the bloodstream and binds specifically to the glycosphingolipid receptor globotriaosylceramide ($\text{Gb}_3$ / CD77) abundantly expressed on glomerular endothelial cells.
   • Receptor-mediated endocytosis internalizes the toxin; the enzymatic A-subunit cleaves a specific adenine residue from 28S rRNA of the 60S ribosomal subunit, halting host protein synthesis and triggering endothelial cell apoptosis and detachment.
   • Denuded subendothelial matrix triggers localized platelet adherence, activation, and microvascular thrombosis (platelet-fibrin thrombi). Passing erythrocytes are mechanically sheared across occluded capillary loops, causing Coombs-negative hemolytic anemia, consumptive thrombocytopenia, and acute ischemic kidney injury.
3. Fractional Excretion of Sodium Calculation:
   $$ > \begin{aligned} > \text{FE}_{\text{Na}} (\%) &= \frac{\text{Urine Sodium} \times \text{Serum Creatinine}}{\text{Serum Sodium} \times \text{Urine Creatinine}} \times 100 \\ > &= \frac{52 \times 3.2}{130 \times 28} \times 100 \\ > &= \frac{166.4}{3640} \times 100 \\ > &= \mathbf{4.57\%} \quad (\text{Normal: } <1\% \text{ in pre-renal azotemia, } >2\% \text{ in intrinsic acute tubular/glomerular injury}) > \end{aligned} > $$
   • Interpretation: $\text{FE}_{\text{Na}} > 2\%$ confirms intrinsic acute kidney injury (acute tubular necrosis/glomerular microvascular occlusion) rather than pre-renal hypovolemic azotemia.
4. Specific Management Directives:
   • Platelet Transfusion: Strictly avoided/contraindicated routinely because infused platelets fuel ongoing microvascular thrombosis; reserved solely for active, life-threatening hemorrhage or immediately prior to invasive surgical procedures (e.g., peritoneal dialysis catheter placement).
   • Antimicrobials & Antimotility Drugs: Antibiotics are contraindicated as bacterial lysis triggers an exponential surge in Shiga toxin release via SOS phage induction, worsening renal outcomes; antimotility agents (e.g., loperamide) prolong gastrointestinal transit and enhance systemic toxin absorption.
   • Renal Replacement Therapy (Peritoneal Dialysis / Hemodialysis): Indicated for refractory hyperkalemia ($>6.5\text{ mEq/L}$ unresponsive to medical measures), symptomatic fluid overload (hypertension, pulmonary edema), severe refractory metabolic acidosis ($\text{pH} < 7.15$), symptomatic uremia (encephalopathy, pericarditis), or persistent anuria/oliguria ($>24–48\text{ hours}$).

1. Spot Urinary Calcium-to-Creatinine Ratio Calculation and Age-Specific Cutoffs:
   

   $$ > \begin{aligned} > \text{Spot }\text{U}_{\text{Ca}}/\text{U}_{\text{Cr}}\text{ Ratio} &= \frac{\text{Urine Calcium (mg/dL)}}{\text{Urine Creatinine (mg/dL)}} \\ > &= \frac{16\text{ mg/dL}}{20\text{ mg/dL}} \\ > &= \mathbf{0.80\text{ mg/mg}} \quad (\text{Normal for }>2\text{ years: } <0.20\text{ mg/mg}) > \end{aligned} > $$
   • Interpretation: Markedly elevated for an 8-year-old child, establishing hypercalciuria.
   • Age-stratified upper limits of normal ($\text{U}_{\text{Ca}}/\text{U}_{\text{Cr}}$):
     • $<6\text{ months}$: $>0.80\text{ mg/mg}$ ($>2.26\text{ mmol/mmol}$)
     • $6\text{ months to } 2\text{ years}$: $>0.50\text{ mg/mg}$ ($>1.41\text{ mmol/mmol}$)
     • $>2\text{ years}$: $>0.20\text{ mg/mg}$ ($>0.56\text{ mmol/mmol}$)

2. Gold Standard 24-Hour Urine Diagnostic Criterion:

   • Urinary calcium excretion exceeding $>4\text{ mg/kg/day}$ ($>0.1\text{ mmol/kg/day}$) while on a regular, unrestricted diet.

3. Pathophysiological Classification of Idiopathic Hypercalciuria:

   • Absorptive Hypercalciuria: Primary intestinal hyperabsorption of calcium, leading to transient postprandial elevation of ionized serum calcium, suppression of parathyroid hormone (PTH), and increased filtered calcium load at the glomerulus.
   • Renal Hypercalciuria: Primary intrinsic tubular defect with impaired calcium reabsorption in the thick ascending limb of Henle or distal convoluted tubule (tubular "calcium leak"), leading to secondary hyperparathyroidism.
   • Resorptive Hypercalciuria: Primary loss of calcium from bone demineralization, characterized by uncoupling of bone resorption and formation with normal or elevated serum calcium.

4. Management Protocol:

   • Non-Pharmacological Measures:
     • High fluid intake: $1.5\text{--}2\text{ L/m}^2/\text{day}$ (or $>2500\text{ mL/day}$) distributed throughout the day and night to maintain a urine specific gravity $<1.010$.
     • Dietary sodium restriction: Restrict to $2\text{--}2.5\text{ mEq/kg/day}$ (low-salt diet). Reduced proximal tubular sodium reabsorption decreases passive co-reabsorption clearance, thus reducing renal calcium loss.
     • Maintain normal age-appropriate calcium intake: Dietary calcium restriction is contraindicated because it induces negative bone balance and increases intestinal oxalate absorption (heightening calcium oxalate nephrolithiasis risk).
   • Pharmacological Therapy (if persistent hematuria, renal colic, or nephrocalcinosis despite dietary therapy):
     • Thiazide Diuretics: Hydrochlorothiazide, oral, $1\text{--}2\text{ mg/kg/day}$ once daily or divided every 12 hours (enhances distal tubular calcium reabsorption and induces volume contraction that augments proximal tubular reabsorption).
     • Potassium Citrate: Oral, $1\text{--}2\text{ mEq/kg/day}$ divided into 2–3 daily doses (corrects thiazide-induced hypokalemia, increases urinary citrate, which complexes urinary calcium into soluble calcium citrate, inhibiting crystal aggregation).

Pathophysiologic Differentiation of Hypercalciuria Subtypes

To differentiate absorptive from renal hypercalciuria, a fasting and calcium-loading test (Pak test) can be utilized:

Suspected Idiopathic Hypercalciuria (Confirmed 24-hr UCa > 4 mg/kg/day)
                         │
                Fasting Spot UCa/UCr
                         │
           ┌─────────────┴─────────────┐
           ▼                           ▼
    Normal (<0.11 mg/mg)        Elevated (>0.11 mg/mg)
           │                           │
   Oral Calcium Load           Fasting Serum PTH
   (1000 mg elemental)                 │
           │                  ┌────────┴────────┐
           ▼                  ▼                 ▼
     UCa/UCr Post-Load     High PTH        Normal PTH
    >0.20 mg/mg: Absorptive   │                 │
    Type I or Type II         ▼                 ▼
                       Renal "Leak"     Resorptive / Other
                       Hypercalciuria      (e.g., VDR defect)

• Absorptive Type I vs Type II: Type I does not normalize hypercalciuria with dietary restriction, whereas Type II normalizes urinary calcium on a calcium-restricted diet ($400\text{ mg/day}$).
• Secondary Causes of Hypercalciuria to Exclude:
  • Distal renal tubular acidosis (Type 1 dRTA)
  • Bartter syndrome (thick ascending limb transport failure)
  • Dent disease (CLCN5 / OCRL mutations)
  • Williams syndrome / Idiopathic infantile hypercalcemia (CYP24A1 mutation)
  • Loop diuretic therapy (Furosemide)
  • Prolonged immobilization

1. Primary Diagnosis & Distinguishing Features:
   • Diagnosis: Cerebral Salt Wasting (CSW) / Cerebral Salt Wasting Syndrome (CSWS).
   • Distinguishing Features from SIADH:
     • Extracellular Volume Status: CSW exhibits clinical hypovolemia/dehydration (hypotension, tachycardia, sunken fontanelle), whereas SIADH is strictly euvolemic or mild hypervolemic without edema.
     • Urine Output: CSW manifests with marked polyuria (>3–4 mL/kg/h), whereas SIADH characteristically causes oliguria or low-normal urine output.
     • Fluid Balance and Weight: CSW leads to net negative fluid balance with rapid weight loss; SIADH leads to fluid retention with weight gain or stable weight.
     • Serum Urea / BUN: Elevated BUN with elevated BUN/creatinine ratio in CSW due to prerenal dehydration; low-to-normal BUN in SIADH due to dilution.
2. Additional Confirmatory Investigations:
   • Central Venous Pressure (CVP) / Inferior Vena Cava (IVC) collapsibility index by bedside echocardiography: Low CVP (<5–6 cm H₂O) or flat/collapsing IVC (>50% collapsibility) confirms hypovolemia in CSW (elevated or normal in SIADH).
   • Serum Uric Acid & Fractional Excretion of Uric Acid (FE-UA): Hypouricemia with elevated FE-UA that persists even after volume correction is specific to CSW (in SIADH, FE-UA normalizes once hyponatremia is corrected).
   • Plasma Brain Natriuretic Peptide (BNP) / Atrial Natriuretic Peptide (ANP): Elevated in CSW due to excessive central or cerebral release of natriuretic peptides.
3. Mathematical Calculation:
   $$ > \begin{aligned} > \text{Total Body Water (TBW)} &= 0.60 \times \text{Weight (kg)} \\ > &= 0.60 \times 8.5\text{ kg} = \mathbf{5.1\text{ L}} \\ > \text{Sodium Deficit (mEq)} &= \text{TBW} \times (\text{Target } [\text{Na}^+] - \text{Measured } [\text{Na}^+]) \\ > &= 5.1\text{ L} \times (135\text{ mEq/L} - 126\text{ mEq/L}) \\ > &= 5.1 \times 9 \\ > &= \mathbf{45.9\text{ mEq}} > \end{aligned} > $$
4. Management Protocol:
   • Emergency Hemodynamic Resuscitation:
     • Bolus of 0.9% Normal Saline (0.9% NaCl, 154 mEq/L Na⁺) at 10–20 mL/kg IV over 30–60 minutes to restore intravascular volume and normalize mean arterial pressure.
     • If symptomatic with neuro-irritability or seizures: 3% Hypertonic Saline (513 mEq/L Na⁺) 2–3 mL/kg IV over 10–20 minutes.
   • Replacement & Maintenance Therapy:
     • Match urinary sodium and fluid losses volume-for-volume (milliliter-for-milliliter) using 0.9% Normal Saline + 20 mEq/L KCl, or hypertonic saline (3% NaCl) titration if polyuria and natriuresis outpace isotonic fluids.
     • Fluid restriction is strictly contraindicated (can precipitate cerebral ischemia, infarction, or hypovolemic shock).
   • Specific Pharmacotherapy:
     • Fludrocortisone: 0.1 to 0.2 mg/day orally or via NG tube (or 5–10 mcg/kg/day divided q12h) to enhance renal tubular sodium reabsorption in refractory salt wasting.
   • Safe Sodium Correction Limit:
     • Rate of serum sodium elevation should not exceed 8–10 mEq/L in 24 hours (and <18 mEq/L in 48 hours) to prevent Central Pontine Myelinolysis / Osmotic Demyelination Syndrome (ODS).

Pathophysiologic Comparison: CSW vs. SIADH

Clinical Warning: Fluid restriction in a patient misdiagnosed with SIADH who actually has CSW will aggravate hypovolemic shock and cause cerebral hypoperfusion/stroke. When in doubt in a neurosurgical or CNS infection patient, volume expansion with isotonic saline is safer than fluid restriction.

1. Expected Renal Metabolic Compensation:
   • Acute Respiratory Acidosis: $\text{HCO}_3^-$ increases by $1\text{ mEq/L}$ for every $10\text{ mm Hg}$ elevation in $\text{PaCO}_2$ above $40\text{ mm Hg}$ (limit $\approx 30\text{ mEq/L}$).
   • Chronic Respiratory Acidosis: $\text{HCO}_3^-$ increases by $3.5\text{ to }4.0\text{ mEq/L}$ for every $10\text{ mm Hg}$ elevation in $\text{PaCO}_2$ above $40\text{ mm Hg}$ (limit $\approx 42\text{ to }45\text{ mEq/L}$).
   • Acute Respiratory Alkalosis: $\text{HCO}_3^-$ decreases by $2\text{ mEq/L}$ for every $10\text{ mm Hg}$ reduction in $\text{PaCO}_2$ below $40\text{ mm Hg}$ (limit $\approx 18\text{ mEq/L}$).
   • Chronic Respiratory Alkalosis: $\text{HCO}_3^-$ decreases by $4\text{ to }5\text{ mEq/L}$ for every $10\text{ mm Hg}$ reduction in $\text{PaCO}_2$ below $40\text{ mm Hg}$ (limit $\approx 12\text{ to }14\text{ mEq/L}$).
2. Bicarbonate Calculation:
   $$ > \begin{aligned} > \Delta\text{PaCO}_2 &= 70 - 40 = 30\text{ mm Hg} \\ > \text{Expected }\Delta[\text{HCO}_3^-] &= 1\text{ mEq/L} \times \left(\frac{30}{10}\right) = 3\text{ mEq/L} \\ > \text{Expected }[\text{HCO}_3^-] &= 24 + 3 = \mathbf{27\text{ mEq/L}} \quad (26\text{--}28\text{ mEq/L}) > \end{aligned} > $$
3. Pathophysiology of Renal Compensation Delay:
   • Hyperacute cellular buffering relies strictly on intracellular non-bicarbonate buffers (hemoglobin, intracellular proteins, and organic phosphates), which yields minimal bicarbonate increment ($1\text{ mEq/L}$ per $10\text{ mm Hg}$ $\text{PaCO}_2$).
   • True renal compensation requires upregulation of apical proximal tubular sodium-hydrogen antiporters ($\text{NHE3}$), enhanced ammoniagenesis, and increased $\text{H}^+$-ATPase excretion, which takes $48\text{ to }72\text{ hours}$ to reach steady state.
4. Pediatric Causes of Chronic Respiratory Acidosis:
   • Bronchopulmonary dysplasia (BPD) / chronic lung disease of infancy.
   • Neuromuscular diseases with progressive hypoventilation (e.g., Spinal Muscular Atrophy, Duchenne Muscular Dystrophy).
   • Severe thoracic deformities (e.g., severe kyphoscoliosis, asphyxiating thoracic dystrophy / Jeune syndrome).
   • Congenital central hypoventilation syndrome (Ondine curse).

1. Primary Diagnosis:
   • Neonatal Renal Vein Thrombosis (RVT) (bilateral).
2. Differential Diagnoses for Neonatal Flank Masses:
   • Congenital bilateral hydronephrosis (e.g., pelviureteric junction obstruction, posterior urethral valves).
   • Autosomal Recessive Polycystic Kidney Disease (ARPKD).
   • Bilateral adrenal hemorrhage.
   • Congenital mesoblastic nephroma (or bilateral Wilms tumor, though rarely presenting on day 3).
   • Renal cystic dysplasia / Multicystic dysplastic kidney (if bilateral or asymmetric).
3. Pathophysiology:
   • Maternal Hyperglycemia: Induces fetal hyperinsulinism, fetal macrosomia, and increased metabolic rate, driving fetal hypoxemia.
   • Erythropoietin Overproduction: Leads to secondary neonatal polycythemia (hematocrit $>65\%$) and significant blood hyperviscosity.
   • Renal Microcirculation Stasis: Hyperviscous blood sluggishly traverses the hyperosmolar medullary peritubular capillary and vasa recta networks, precipitating endothelial shear stress, platelet consumption (thrombocytopenia), and microvascular thrombus initiation that propagates retrograde into the main renal veins.
4. Management Protocol:
   • Supportive & Hemodynamic Stabilization:
     • Partial exchange transfusion with $0.9\%$ normal saline to reduce hematocrit to safe levels ($<55\text{--}60\%$).
     • Strict fluid and electrolyte balance; renal replacement therapy (peritoneal dialysis) if refractory hyperkalemia, fluid overload, or persistent anuria supervenes.
   • Anticoagulation Regimen (Bilateral RVT / Extension into Inferior Vena Cava):
     • Unfractionated Heparin (UFH) initial loading dose of $75\text{ units/kg}$ IV over 10 minutes, followed by a continuous infusion of $28\text{ units/kg/h}$, titrated to target anti-Xa levels ($0.35\text{--}0.7\text{ U/mL}$) or aPTT $60\text{--}85\text{ seconds}$.
     • Transition to Low-Molecular-Weight Heparin (Enoxaparin): $1.5\text{--}2.0\text{ mg/kg/dose}$ subcutaneously every 12 hours (titrated to anti-Xa target of $0.5\text{--}1.0\text{ U/mL}$ checked 4 hours post-dose), continued for 6 weeks to 3 months.
     • Systemic thrombolytic therapy (Tissue Plasminogen Activator / Alteplase: $0.1\text{ to }0.5\text{ mg/kg/h}$ IV for 6 hours) is reserved exclusively for life-threatening bilateral RVT with complete anuria or imminent thrombus propagation to the right atrium.

1. Definitive Diagnosis & Defining Triad:
   • Diagnosis: Nephrotic Syndrome (likely Minimal Change Disease).
   • Classic Triad / Tetrad:
     • Nephrotic-range proteinuria (urine protein-to-creatinine ratio $>2\text{ mg/mg}$, or $>40\text{ mg/m}^2/\text{h}$, or $3+/4+$ on dipstick).
     • Hypoalbuminemia (serum albumin $<2.5\text{ g/dL}$, strictly $<3.0\text{ g/dL}$).
     • Generalized edema (anasarca).
     • (Associated hypercholesterolemia / dyslipidemia).
2. Indications for Renal Biopsy:
   • Age at onset $<1\text{ year}$ (infantile/congenital) or $>12\text{ years}$.
   • Persistent microscopic or macroscopic hematuria, persistent hypertension, or sustained renal failure without volume depletion.
   • Low serum complement C3/C4 levels.
   • Steroid resistance (lack of complete remission despite 4 weeks of daily prednisolone followed by 2–3 pulses of methylprednisolone).
   • Prior to initiating Calcineurin Inhibitor therapy in steroid-dependent or frequent-relapsing nephrotic syndrome.
3. Infection & Antimicrobial Therapy:
   • Pathogen: Streptococcus pneumoniae (Pneumococcus); second commonest: Escherichia coli / Gram-negative bacilli.
   • Antibiotic Regimen: Cefotaxime ($150\text{ mg/kg/day}$ IV divided every 6 to 8 hours) OR Ceftriaxone ($75\text{ to }100\text{ mg/kg/day}$ IV once daily or divided every 12 hours) for $10\text{ to }14\text{ days}$.
4. Steroid Induction & Steroid-Sparing Regimen:
   • Induction (ISPN / KDIGO 2021 update):
     • Oral Prednisolone: $2\text{ mg/kg/day}$ (or $60\text{ mg/m}^2/\text{day}$; maximum $60\text{ mg/day}$) as a single morning dose for 6 weeks.
     • Followed by $1.5\text{ mg/kg}$ (or $40\text{ mg/m}^2$; maximum $40\text{ mg}$) on alternate days for 6 weeks, then tapered and discontinued over the subsequent 4–8 weeks.
   • Steroid-Sparing Agents for Steroid-Dependent Nephrotic Syndrome:
     • Calcineurin Inhibitors (CNIs): Tacrolimus ($0.1\text{ to }0.15\text{ mg/kg/day}$ PO divided q12h, target trough $4\text{--}8\text{ ng/mL}$) OR Cyclosporine ($4\text{ to }5\text{ mg/kg/day}$ PO divided q12h, target trough $80\text{--}120\text{ ng/mL}$).
     • Anti-CD20 Monoclonal Antibody: Rituximab ($375\text{ mg/m}^2$ IV infusion, 1 to 2 doses given 1–2 weeks apart).
     • Alkylating agents / Antimetabolites: Cyclophosphamide ($2\text{ mg/kg/day}$ PO for 12 weeks) OR Mycophenolate Mofetil (MMF: $1200\text{ mg/m}^2/\text{day}$ PO divided q12h).

1. Radiological Findings & Anatomical Diagnosis:
   • MCU Findings: Elongated, pointed bladder dome with an irregular, serrated wall outline showing prominent detrusor trabeculations, multiple pseudo-diverticula/saccular out-pouchings, and an elongated vertical axis ("Christmas tree" or "fir-tree" shaped bladder).
   • Diagnosis: Neurogenic or severe non-neurogenic functional bladder outlet obstruction with detrusor hypertrophy.
2. Hinman Syndrome:
   • Definition: Non-neurogenic neurogenic bladder (also termed dysfunctional voiding syndrome or Hinman-Allen syndrome), characterized by functional bladder outlet obstruction in the complete absence of any anatomical, neurological, or spinal cord abnormality.
   • Urodynamic Finding: Detrusor-sphincter dyssynergia (involuntary contraction of the external urethral sphincter during detrusor contraction during micturition), resulting in elevated intravesical pressures, bilateral hydroureteronephrosis, and vesicoureteral reflux.
3. Essential Procedural Intervention:
   • Intervention: Clean Intermittent Catheterization (CIC) / Clean Intermittent Self-Catheterization (CISC).
   • Frequency: 4 to 6 times per day (every 3 to 4 hours during waking hours, and prior to bedtime) to maintain catheterized volumes below expected capacity and intravesical pressure $<40\text{ cm H}_2\text{O}$.
4. Pharmacotherapy:
   • Anticholinergics / Antimuscarinics:
     • Oxybutynin: $0.2\text{ to }0.4\text{ mg/kg/day}$ PO divided every 8 to 12 hours (maximum $15\text{ mg/day}$).
     • Tolterodine: $0.1\text{ to }0.2\text{ mg/kg/day}$ PO divided every 12 hours (or $1\text{--}2\text{ mg}$ once to twice daily).
   • $\beta_3$-Adrenergic Receptor Agonists:
     • Mirabegron: $25\text{ to }50\text{ mg}$ PO once daily (in children $>35\text{ kg}$ or $>11\text{ years}$ off-label).
   • $\alpha_1$-Adrenergic Antagonists (to reduce bladder neck resistance):
     • Tamsulosin: $0.2\text{ to }0.4\text{ mg}$ PO once daily.

1. Expected Bladder Capacity (EBC):
   $$ > \begin{aligned} > \text{Bladder Capacity (Koff formula)} &= (\text{Age in years} + 1) \times 30\text{ mL} \\ > &= (4 + 1) \times 30 = \mathbf{150\text{ mL}} \\ > \text{Alternative (Hjälmås formula)} &= (\text{Age in years} + 2) \times 30\text{ mL} \\ > &= (4 + 2) \times 30 = \mathbf{180\text{ mL}} > \end{aligned} > $$
2. Significant Post-Void Residual (PVR) Threshold:
   • A single post-void residual volume $>20\text{ mL}$ (or $>10\%$ of bladder capacity).
   • Repeated post-void residual volume $>2\text{ mL/kg}$ ($>44\text{ mL}$ in this $22\text{ kg}$ child).
3. Estimated GFR (Bedside Schwartz):
   $$ > \begin{aligned} > \text{eGFR} &= \frac{k \times \text{Height (cm)}}{\text{Serum Creatinine (mg/dL)}} \\ > &= \frac{0.413 \times 100}{1.0} \\ > &= \mathbf{41.3\text{ mL/min}/1.73\text{ m}^2} > \end{aligned} > $$
   • Interpretation: This eGFR is significantly reduced (severely decreased; corresponds to CKD Stage G3b/G4). For a 4-year-old child, normal mean GFR is $90\text{ to }120\text{ mL/min}/1.73\text{ m}^2$, and normal serum creatinine is approximately $0.3\text{ to }0.5\text{ mg/dL}$.
4. Nuclear Medicine Renal Scintigraphy:
   • Gold-Standard Tracer: $^{99\text{m}}\text{Tc}$-DMSA (Dimercaptosuccinic acid) renal cortical scintigraphy.
   • Optimal Timing Post-Pyelonephritis: At least 4 to 6 months after the resolution of acute pyelonephritis (to distinguish transient acute inflammatory photon defects from permanent chronic cortical fibrotic scarring).

1. Investigation and Radiopharmaceuticals:
   • Investigation: Diuretic dynamic renal scintigraphy (Diuretic Renogram / $F+20$ or $F-15$ renography).
   • Radiopharmaceuticals:
     • $^{99\text{m}}\text{Tc}$-MAG3 (Mercaptoacetyltriglycine): Cleared predominantly by proximal tubular secretion (~95%); preferred agent in neonates, infants, and patients with impaired renal function.
     • $^{99\text{m}}\text{Tc}$-EC (Ethylene dicysteine): High renal extraction with pure tubular excretion; performance comparable to MAG3.
     • $^{99\text{m}}\text{Tc}$-DTPA (Diethylenetriamine pentaacetate): Cleared exclusively by glomerular filtration (~100%); provides simultaneous measurement of GFR.
2. Renogram Parameters:
   • $T_{\max}$: Time from intravenous radiotracer injection to the peak count rate on the parenchymal region-of-interest activity curve (normal: $<5\text{ minutes}$).
   • $T_{1/2}$ (Drainage Half-Time): Time required for peak renal activity to decrease by 50% following intravenous furosemide administration:
     • Normal washout: $<10\text{ minutes}$.
     • Equivocal / Partial delay: $10\text{ to }20\text{ minutes}$.
     • Obstructed washout: $>20\text{ minutes}$.
   • IRT / Parenchymal Transit Time: Time taken for the radiopharmaceutical to traverse the renal cortex and enter the collecting system (normal: $2\text{ to }4\text{ minutes}$; prolonged in intrinsic parenchymal injury or profound stasis).
3. Diagnostic Criteria for Significant Obstruction:
   • Washout dynamics: Diuretic renogram curve demonstrating an obstructive pattern (persistent rising or plateauing tracer retention after furosemide challenge with $T_{1/2} > 20\text{ minutes}$).
   • Split Renal Function (SRF): Depressed differential function of the affected kidney ($<40\%$), or a documented progressive decline $>5\%$ on sequential scans.
   • Anatomical progression: Progressive pelvic dilatation on serial ultrasound (APPD $>20\text{ to }30\text{ mm}$ or escalating Society for Fetal Urology [SFU] Grade 3–4 hydronephrosis).
4. Surgical Management:
   • Gold-standard procedure: Anderson-Hynes dismembered pyeloplasty (performed via open, laparoscopic, or robot-assisted approach) to resect the aperistaltic adynamic junction and tailor the dilated renal pelvis.
   • Indications: Symptomatic Dietl's crisis, compromised split renal function ($<40\%$), or serial functional deterioration.
   • Stenting protocol: Placement of an internal double-J (DJ) ureteral stent across the neo-anastomosis for 4 to 6 weeks, accompanied by a temporary bladder catheter for 24 to 48 hours postoperatively.

1. Investigation and Diagnosis:
   • Investigation: Voiding Cystourethrogram (VCUG) / Micturating Cystourethrogram (MCU).
   • Diagnosis: Posterior Urethral Valves (PUV) (Type I Young classification).
2. Radiological Abnormalities:
   • Elongated and severely dilated posterior urethra proximal to the site of obstruction.
   • Caliber discrepancy with abrupt caliber transition at the level of the external urethral sphincter (valve leaflets).
   • Thickened, heavily trabeculated bladder wall with pseudodiverticula ("Christmas tree" / pine-cone configuration).
   • Bladder neck muscular hypertrophy producing a prominent posterior lip.
   • Secondary vesicoureteral reflux (VUR) (seen in ~50% of cases, often high-grade).
3. Mathematical Calculation:
   $$ > \begin{aligned} > \text{eGFR} &= \frac{k \times \text{Length (cm)}}{\text{Serum Creatinine (mg/dL)}} \\ > &= \frac{0.413 \times 50}{1.4} = \frac{20.65}{1.4} \\ > &= \mathbf{14.75\text{ mL/min/1.73 m}^2} \quad (\text{Reference mean term neonate day 5: } 30\text{--}50\text{ mL/min/1.73 m}^2) > \end{aligned} > $$
4. Management Protocol:
   • Immediate stabilization:
     • Bladder decompression using a 5–6 Fr infant feeding tube (avoid Foley catheters because the balloon can occlude the ureteric orifices or trigger violent trigonal spasms).
     • Fluid and electrolyte balance: Monitor for post-obstructive diuresis; replace urinary sodium and volume losses with 0.45% normal saline containing potassium as guided by serum chemistries.
     • Antibiotic prophylaxis: Amoxicillin 10–15 mg/kg/day orally once daily or Cephalexin 10 mg/kg/day orally once daily.
   • Definitive surgical therapy:
     • Primary transurethral valve ablation: Endoscopic division/ablation at the 5, 7, or 12 o'clock positions using cold knife incision, Bugbee electrocautery, or holmium laser once the infant is metabolically stabilized and the urethra accommodates a 7.5–9 Fr cystourethroscope.
     • Temporary diversion: Cutaneous vesicostomy (Blocksom technique) if the neonate is premature, weighing $<2.5\text{ kg}$, has an impassable urethra, or exhibits refractory urosepsis/progressive azotemia despite tube drainage.

1. Dipstick Confounders:
   • False-positive results:
     • Gross hematuria or pyuria (release of intracellular/leukocyte proteins).
     • Highly concentrated urine (specific gravity $>1.030$).
     • Highly alkaline urine ($\text{pH} > 8.0$, which overcomes the buffer system of the tetrabromophenol blue indicator).
     • Contamination with quaternary ammonium skin disinfectants or chlorhexidine.
   • False-negative results:
     • Very dilute urine (specific gravity $<1.005$).
     • Non-albumin proteinuria (e.g., tubular low-

1. Diagnosis & Classic Triad:

   • Diagnosis: Prune-Belly syndrome (Eagle-Barrett syndrome / Triad syndrome / Abdominal muscle deficiency syndrome).
   • Classic Triad:
     • Deficiency, hypoplasia, or partial absence of abdominal wall musculature.
     • Bilateral intra-abdominal cryptorchidism (undescended testes).
     • Complex urinary tract anomalies (hydroureteronephrosis, megacystis, megaureters).

2. Characteristic Urinary Tract Abnormalities:

   • Urinary Bladder: Megacystis (large-capacity, thick-walled, non-trabeculated bladder) with an open bladder neck; frequent patent urachus or urachal diverticulum.
   • Ureters: Markedly elongated, tortuous, and dilated ureters (megaureter) with deficient smooth muscle and disorganized peristalsis (predominantly distal).
   • Urethra: Prostatic hypoplasia with marked dilation of the prostatic urethra (megalourethra) tapering at the membranous junction without true mechanical posterior urethral valves.
   • Kidneys & Vesicoureteral Junction: High-grade vesicoureteral reflux (VUR) in up to 75% of cases; varying degrees of renal dysplasia (Potter type II or IV) and hydronephrosis.

3. Embryological Hypotheses:

   • Primary Mesodermal Defect Hypothesis: Generalized arrest of lateral mesodermal differentiation between the 6th and 10th weeks of fetal gestation, simultaneously affecting abdominal wall muscles, ureteric/bladder smooth muscle, and gubernaculum development.
   • Lower Urinary Tract Obstruction (LUTO) Hypothesis: Transient early mechanical or functional fetal bladder outlet obstruction leading to massive bladder distension; this causes compressive atrophy of the overlying abdominal wall and prevents testicular transabdominal descent.

4. Primary Early Neonatal Complication:

   • Pulmonary Hypoplasia: The leading cause of immediate neonatal mortality (responsible for ~20% of perinatal deaths).
   • Pathogenesis: Severe oligohydramnios secondary to fetal renal dysplasia and reduced urine output (Potter sequence) leads to uterine compression of the fetal thorax and lack of amniotic fluid inhalation, which arrests normal alveolar branching, resulting in pulmonary hypoplasia, refractory respiratory failure, and high risk of fatal tension pneumothorax.

5. Woodard Clinical Staging System:

   • Category 1 (Severe / Fatal): Severe oligohydramnios, severe renal dysplasia, complete urethral obstruction, and severe pulmonary hypoplasia. Typically stillborn or dying within the first 24–48 hours of life despite maximal support.
   • Category 2 (Moderate / Classic Form): Typical triad features with moderate bilateral hydroureteronephrosis and variable renal parenchymal impairment. Preserved lung function; at high risk of progressive renal deterioration and recurrent urosepsis without structured urological care.
   • Category 3 (Mild / Incomplete Form): Mild, incomplete abdominal wall defect, normal or minimally impaired renal function, mild urinary tract dilatation, preserved lung volume, and absent pulmonary hypoplasia. Best long-term prognosis.

6. Initial Medical and Surgical Management:

   • Medical Stabilization:
     • Respiratory care: Gentle mechanical ventilation; avoid high peak inspiratory pressures to prevent pneumothorax in hypoplastic lungs.
     • Continuous bladder drainage via urethral catheterization (8 Fr feeding tube or silicon Foley) to relieve retention and monitor urine output.
     • Continuous antibiotic prophylaxis: Oral Amoxicillin ($10\text{--}15\text{ mg/kg/day}$ once daily in neonates $<2\text{ months}$) or Cephalexin to prevent urosepsis.
     • Renal function and electrolyte monitoring (serum creatinine nadir, electrolytes, blood gas).
   • Surgical Indications:
     • Urgent cutaneous diversion (cutaneous vesicostomy or high loop ureterostomy) is indicated only if bladder catheter drainage fails to decompress the upper tracts, in the presence of refractory urosepsis, or with progressive azotemia.
     • Reconstructive surgery (abdominoplasty, extensive ureteral tailoring/reimplantation, and transabdominal orchiopexy) is non-emergent and deferred to $6\text{--}12\text{ months}$ of age.

graph TD
    A[Fetal Mesodermal Dysgenesis or Early LUTO] --> B[Severe Megacystis & Urinary Stasis]
    A --> C[Abdominal Muscular Agenesis]
    A --> D[Gubernacular Failure]
    
    B --> E[Fetal Oligohydramnios]
    B --> F[Bilateral Megaureter & Hydronephrosis]
    C --> G[Wrinkled, Lax Abdominal Wall]
    D --> H[Bilateral Intra-abdominal Cryptorchidism]
    
    E --> I[Potter Sequence / Pulmonary Hypoplasia]
    I --> J[Immediate Neonatal Respiratory Distress / Pneumothorax]
    F --> K[Renal Dysplasia & Early Urosepsis]

• Prognostic Factor: The baseline serum creatinine nadir achieved during the first year of life is the strongest prognostic indicator for long-term renal survival. A nadir serum creatinine $>0.7\text{ mg/dL}$ ($>62\,\mu\text{mol/L}$) at 1 year strongly predicts progression to end-stage renal disease (ESRD) requiring renal replacement therapy before adolescence.

1. Modality of Choice per Clinical Presentation:

   • Case A: $^{99\text{m}}\text{Tc}$-Dimercaptosuccinic acid ($^{99\text{m}}\text{Tc}$-DMSA) static renal cortical scintigraphy.
   • Case B: Micturating Cystourethrogram (MCU / Fluoroscopic Voiding Cystourethrography).
   • Case C: Ultrasonography of Kidney, Ureter, and Bladder (USG KUB) supplemented by Low-Dose Non-Contrast Computed Tomography (NCCT KUB).
   • Case D: Dynamic diuretic renal scintigraphy ($^{99\text{m}}\text{Tc}$-MAG3 or $^{99\text{m}}\text{Tc}$-DTPA renography with furosemide administration).

2. Comparison of Renal Scintigraphy Radiotracers:

   • $^{99\text{m}}\text{Tc}$-DMSA (Static Agent):
     • Mechanism of Renal Handling: Binds avidly to proximal tubular cells within the renal cortex; $<10\%$ excreted into the urine under normal transit.
     • Primary Indication: Assessment of functioning cortical mass, detection of acute focal pyelonephritis, renal parenchymal scarring, and split (differential) renal function.
   • $^{99\text{m}}\text{Tc}$-DTPA (Dynamic Agent):
     • Mechanism of Renal Handling: Cleared exclusively by glomerular filtration ($100\%$ GFR) without tubular secretion or reabsorption.
     • Primary Indication: Measurement of Glomerular Filtration Rate (GFR) and evaluation of drainage kinetics in older infants/children with normal renal function.
   • $^{99\text{m}}\text{Tc}$-MAG3 (Dynamic Agent):
     • Mechanism of Renal Handling: Cleared predominantly by active tubular secretion ($\sim 90\%$) with high first-pass extraction fraction.
     • Primary Indication: Dynamic evaluation of suspected pelviureteric junction obstruction (PUJO) or vesicoureteric junction obstruction (VUJO), preferred in neonates, infants $<1\text{ year}$, or patients with impaired GFR.

3. Procedural Checklist for $^{99\text{m}}\text{Tc}$-DMSA Scintigraphy:

   • Timing: Perform at least 4 to 6 months after the acute episode of febrile pyelonephritis (to prevent misinterpreting transient acute inflammatory photon-deficient defects as permanent irreversible scarring).
   • Prerequisites: Ensure active infection is treated with documentation of sterile urine culture; child must be afebrile.
   • Hydration: Maintain adequate pre-procedural oral or IV hydration.
   • Dosing: Administer weight-adjusted intravenous dose of $^{99\text{m}}\text{Tc}$-DMSA ($1.85\text{ MBq/kg}$ or $0.05\text{ mCi/kg}$; minimum dose $18.5\text{ MBq}$ / $0.5\text{ mCi}$).
   • Acquisition Timing: Acquire static images 2 to 4 hours post-tracer administration (to permit adequate cortical fixation and optimal background clearance).
   • Imaging Views: Obtain high-resolution parallel-hole or pinhole collimator images in Posterior, Anterior, Left Posterior Oblique (LPO), and Right Posterior Oblique (RPO) projections.

4. Diuretic Renography Parameters:

   • Furosemide Dosing:
     $$ > \text{Dose} = 1.0\text{ mg/kg IV} \quad (\text{Maximum single dose: } 20\text{ to }40\text{ mg}) > $$
   • Washout Half-Time ($T_{1/2}$) Interpretation:
     • Non-obstructed (Normal):
       $$T_{1/2} < 10\text{ minutes}$$
     • Equivocal / Indeterminate:
       $$T_{1/2} = 10\text{ to }20\text{ minutes}$$
     • Obstructed Drainage:
       $$T_{1/2} > 20\text{ minutes}$$

Dynamic Scintigraphy Diuretic Protocols (F-Protocols)

• F+20 Protocol: Standard protocol where furosemide is injected 20 minutes after tracer injection once the collecting system is full.
• F-15 Protocol: Furosemide administered 15 minutes prior to radiotracer injection; useful when maximal diuresis is desired at the exact moment tracer enters the pelvicalyceal system to avoid false-positive obstructive curves caused by large-capacity, compliant renal pelves.
• F-0 Protocol: Simultaneous administration of furosemide and radiotracer.

MCU / VCUG Indications in Pediatric UTIs (Revised Guidelines)

• Recommended following the first febrile UTI if:
  • Renal and bladder ultrasound (RBUS) reveals hydronephrosis, parenchymal thinning, ureteral dilatation, or bladder wall thickening.
  • Atypical organism (non-E. coli species like Proteus, Pseudomonas, or Klebsiella).
  • Associated septic shock or poor stream/voiding dysfunction.
• Always performed following a second febrile UTI regardless of baseline ultrasound findings.

1. Radiographic Features:
   • Exhibit A (Left Kidney): Marked pelvicalyceal dilatation (ballooning of renal pelvis with blunted calyces) with an abrupt cutoff and non-visualization of contrast in the proximal left ureter ("flower-vase" or classical pelviureteric cutoff appearance).
   • Exhibit B (Urinary Bladder): Well-circumscribed, round/oval filling defect in the base of the urinary bladder with surrounding radiolucent halo, representing the classical "cobra-head" or "spring-onion" sign.
2. Definitive Anatomical Diagnoses:
   • Exhibit A: Left-sided Pelviureteric Junction (PUJ) Obstruction.
   • Exhibit B: Intravesical (orthotopic) Ureterocele.
3. Functional Nuclear Study & Drainage Parameter:
   • Study: Dynamic Renal Scintigraphy using $^{99\text{m}}\text{Tc}$-MAG3 (Mercaptoacetyltriglycine) or $^{99\text{m}}\text{Tc}$-EC (Ethylene dicysteine) with Furosemide administration ($F+20$ or $F-15$ protocol; diuretic renography).
   • Quantitative Parameter: Clearance half-time ($T_{1/2}$) following intravenous furosemide:
     • $T_{1/2} > 20\text{ minutes}$ definitively confirms mechanical obstruction.
     • $T_{1/2} < 10\text{ minutes}$ indicates non-obstructive dilatation.
     • $T_{1/2}$ between 10–20 minutes is indeterminate.
4. Definitive Surgical Management:
   • Left PUJ Obstruction: Anderson-Hynes Dismembered Pyeloplasty (open, laparoscopic, or robot-assisted) with excision of the aperistaltic stenotic segment, reduction of redundant pelvis, and transposition over a double-J (DJ) stent.
   • Intravesical Ureterocele: Primary endoscopic transurethral puncture/incision (deroofing) of the ureterocele using a diathermy bugbee electrode or holmium laser.

graph TD
    A[Suspected Pediatric Hydronephrosis] --> B[Renal Bladder Ultrasound]
    B --> C[Pelvic Dilatation with Normal Ureter]
    B --> D[Distal Ureteric Ballooning in Bladder]
    C --> E[Diuretic Renogram: 99mTc-MAG3 / EC with Lasix]
    D --> F[Endoscopic Decompression / Ureterocele Incision]
    E -->|T 1/2 > 20 min or Split Function Drop| G[Anderson-Hynes Dismembered Pyeloplasty]
    E -->|T 1/2 < 10 min| H[Conservative Ultrasonographic Monitoring]

1. Imaging Modality & Radiopharmaceutical:
   • $^{99\text{m}}\text{Tc}$-DMSA (Technetium-99m Dimercaptosuccinic Acid) Static Renal Cortical Scintigraphy.
2. Anatomical Diagnosis & Findings:
   • Diagnosis: Ectopic Right Kidney (Pelvic Kidney) with an orthotopic normal left kidney.
   • Findings: Normal radiotracer uptake and contour in the left renal fossa; absence of renal cortical uptake in the right renal fossa with functioning renal cortical tissue identified low in the right iliac fossa/pelvis.
3. Scan Timing & Physiologic Mechanism:
   • Timing: Static images are acquired 2 to 4 hours post-intravenous injection of $^{99\text{m}}\text{Tc}$-DMSA.
   • Mechanism: Radiopharmaceutical binds to plasma proteins, filters minimally at the glomerulus, and is extracted by peritubular capillaries into the renal cortex, binding specifically to sulfhydryl groups in the proximal convoluted tubular epithelial cells (intracellular retention with negligible excretion into collecting system, yielding high cortical-to-background contrast).
4. Clinical Indications & Distinction from Dynamic Renography:
   • Four Indications:
     • Detection and localization of acute pyelonephritis (focal or diffuse areas of photopenia / cold defects).
     • Detection and quantification of permanent renal cortical scarring (assessed $\ge 4\text{ to }6\text{ months}$ after acute febrile UTI).
     • Accurate quantification of split (differential) renal cortical function.
     • Identification of renal parenchymal variants and anomalies (ectopic kidney, horseshoe kidney, cross-fused ectopia, dysplastic or pseudotumor tissue).
   • Distinction:
     • $^{99\text{m}}\text{Tc}$-DMSA provides static high-resolution anatomic evaluation of functioning renal cortical mass and scarring.
     • Dynamic agents ($^{99\text{m}}\text{Tc}$-DTPA / $^{99\text{m}}\text{Tc}$-MAG3) undergo rapid glomerular filtration or tubular secretion with minimal cortical retention, designed to evaluate dynamic drainage, collecting system transit kinetics, and mechanical outflow obstruction.

1. Definitive Diagnosis:
   • Distal (Type 1) Renal Tubular Acidosis (Classic dRTA) presenting with hypokalemic hyperchloremic (normal anion gap) metabolic acidosis, secondary refractory hypophosphatemic rickets, and medullary nephrocalcinosis.
2. Urine Anion Gap Calculation & Interpretation:
   $$ > \begin{aligned} > \text{Urine Anion Gap (UAG)} &= (\text{U}_{\text{Na}^+} + \text{U}_{\text{K}^+}) - \text{U}_{\text{Cl}^-} \\ > &= (44 + 26) - 32 \\ > &= \mathbf{+38\text{ mEq/L}} \quad (\text{Normal: Negative value, } -20 \text{ to } -50\text{ mEq/L}) > \end{aligned} > $$
   • Significance: Urinary ammonium ($\text{NH}_4^+$) is excreted alongside chloride ($\text{Cl}^-$). In gastrointestinal bicarbonate loss (e.g., diarrhea), intact renal ammoniagenesis increases urinary $\text{NH}_4\text{Cl}$, driving urinary $\text{Cl}^-$ well above $(\text{Na}^+ + \text{K}^+)$, yielding a negative UAG ($-20$ to $-50\text{ mEq/L}$). A positive UAG in the setting of systemic metabolic acidosis proves defective distal urinary acidification and impaired ammonium excretion, establishing renal tubular acidosis.
3. Molecular Defect & Pathophysiology of Nephrocalcinosis:
   • Defect: Failure of $\alpha$-intercalated cells in the cortical and medullary collecting duct to secrete $\text{H}^+$ ions into the tubular lumen due to mutations in the apical vacuolar $\text{H}^+$-ATPase pump, $\text{H}^+/\text{K}^+$-ATPase, or basolateral chloride-bicarbonate exchanger 1 (AE1/SLC4A1).
   • Nephrocalcinosis Mechanism:
     • Chronic systemic metabolic acidosis causes bone buffering dissolution, releasing calcium and phosphate (causing hypercalciuria).
     • Acidosis also stimulates proximal tubular reabsorption of citrate via sodium-dicarboxylate cotransporter 1 (NaDC-1), resulting in severe hypocitraturia (loss of natural calcium-chelating inhibitor).
     • The combination of alkaline urine ($\text{pH} > 5.5$), hypercalciuria, and hypocitraturia induces spontaneous precipitation of calcium phosphate (apatite) crystals within renal parenchyma, causing nephrocalcinosis. Proximal RTA (Type 2) retains the ability to acidify urine distally and does not exhibit severe hypocitraturia, sparing the kidneys from nephrocalcinosis.
4. Medical Management Protocol:
   • Alkali Therapy:
     • Sodium bicarbonate or Potassium citrate/Sodium citrate solution (Bicitra / Shohl's solution).
     • Dose: 2 to 4 mEq/kg/day of base orally, divided into 3 to 4 doses throughout the 24-hour cycle.
   • Potassium Supplementation:
     • Use Potassium citrate (preferred over potassium chloride) at 1 to 2 mEq/kg/day to correct hypokalemia and simultaneously treat hypocitraturia.
     • Caution: Correct severe hypokalemia prior to or alongside alkali therapy to prevent worsening muscle weakness/arrhythmias driven by intracellular potassium shifting.
   • Therapeutic Targets: Maintain serum bicarbonate between $22\text{--}24\text{ mEq/L}$, normalize serum potassium ($3.5\text{--}5.0\text{ mEq/L}$), correct hypercalciuria (urinary calcium:creatinine ratio $<0.2\text{ mg/mg}$), heal rachitic lesions, and restore linear growth velocity.

1. Serum Anion Gap Calculations:
   $$ > \begin{aligned} > \text{Standard SAG} &= \text{Na}^+ - (\text{Cl}^- + \text{HCO}_3^-) \\ > &= 138 - (102 + 8) \\ > &= \mathbf{28\text{ mEq/L}} \quad (\text{Reference range: } 8\text{--}12\text{ mEq/L}) > \end{aligned} > $$
   $$ > \begin{aligned} > \text{Corrected SAG} &= \text{Calculated SAG} + 2.5 \times (4.0 - \text{Serum Albumin in g/dL}) \\ > &= 28 + 2.5 \times (4.0 - 2.0) \\ > &= 28 + 5 \\ > &= \mathbf{33\text{ mEq/L}} > \end{aligned} > $$
2. Respiratory Compensation (Winter's Formula):
   $$ > \begin{aligned} > \text{Expected }\text{pCO}_2 &= (1.5 \times [\text{HCO}_3^-]) + 8 \pm 2 \\ > &= (1.5 \times 8) + 8 \pm 2 \\ > &= 12 + 8 \pm 2 = \mathbf{18\text{ to }22\text{ mm Hg}} > \end{aligned} > $$
   • Patient's observed $\text{pCO}_2$ is $22\text{ mm Hg}$, falling precisely within the expected range, indicating adequate respiratory compensation without an underlying primary respiratory acidosis or alkalosis.
3. Classification of Acidosis:
   • Severe acute secretory rotavirus diarrhea: NAGMA (Hyperchloremic)
   • Methylmalonic acidemia: HAGMA
   • Acetazolamide therapy: NAGMA (Hyperchloremic)
   • Diabetic ketoacidosis: HAGMA
   • Chronic distal renal tubular acidosis: NAGMA (Hyperchloremic)
4. Delta Ratio Calculation & Interpretation:
   $$ > \begin{aligned} > \text{Delta Ratio} &= \frac{\Delta\text{AG}}{\Delta\text{HCO}_3^-} = \frac{\text{Corrected AG} - 12}{24 - \text{Patient's }\text{HCO}_3^-} \\ > &= \frac{33 - 12}{24 - 8} = \frac{21}{16} \\ > &= \mathbf{1.31} > \end{aligned} > $$
   • Interpretation: A Delta Ratio between 1.0 and 2.0 indicates an uncomplicated, pure High Anion Gap Metabolic Acidosis (HAGMA).
     • Values $< 1.0$ indicate concurrent mixed NAGMA with HAGMA (bicarbonate drops disproportionately).
     • Values $> 2.0$ signify concurrent metabolic alkalosis or pre-existing chronic compensated respiratory acidosis (bicarbonate higher than expected for the degree of anion gap elevation).

1. Primary Diagnosis & Surgical Differentials:
   • Primary Diagnosis: Spontaneous Bacterial Peritonitis (SBP) complicating Nephrotic Syndrome.
   • Surgical Differentials: Acute appendicitis with perforation; Acute gangrenous bowel ischemia / volvulus / intussusception.
2. Ascitic Tap Diagnostic Criteria & Distinction:
   • Confirmation of SBP:
     • Ascitic fluid absolute Polymorphonuclear (PMN) neutrophil count $\mathbf{\ge 250\text{ cells/}\mu\text{L}}$ (or total WBC count $>500/\mu\text{L}$ with $>50\%$ neutrophils).
     • Positive ascitic fluid bacterial culture (usually monomicrobial).
   • Distinction from Secondary Peritonitis (Runyon's Criteria):
     • Secondary peritonitis typically demonstrates at least 2 of the following: ascitic total protein $>1.0\text{ g/dL}$, glucose $<50\text{ mg/dL}$, and lactate dehydrogenase (LDH) greater than upper limit of normal for serum; and is polymicrobial on Gram stain/culture. SBP in nephrotic syndrome is typically monomicrobial with very low total protein ($<1.0\text{ g/dL}$) and normal glucose.
3. Causative Microorganisms:
   • Streptococcus pneumoniae (Pneumococcus) — most common ($\approx 50\%$).
   • Escherichia coli and other Gram-negative enteric bacilli (Klebsiella pneumoniae) — second most common ($\approx 25\text{--}30\%$).
4. Resuscitation & Empirical Antimicrobial Protocol:
   • Fluid Resuscitation:
     • 20% Salt-Poor Albumin at $0.5\text{ to }1.0\text{ g/kg}$ ($2.5\text{ to }5\text{ mL/kg}$) IV infused over 1 to 2 hours with simultaneous intravenous crystalloid bolus ($10\text{ mL/kg}$ balanced isotonic crystalloid over 20 minutes) to correct hypovolemia/shock.
   • Empirical Antibiotic Therapy:
     • Ceftriaxone: $75\text{ to }100\text{ mg/kg/day}$ IV in 1 to 2 divided doses (or Cefotaxime $150\text{ to }200\text{ mg/kg/day}$ IV divided every 6 to 8 hours).
     • Plus/Minus Vancomycin: $40\text{ to }60\text{ mg/kg/day}$ IV divided every 6 hours if cephalosporin-resistant pneumococci or MRSA are suspected.
     • Duration: 10 to 14 days of parenteral antimicrobial therapy (tailored to culture and susceptibility results).
   • Steroid Modification:
     • Do not stop oral steroids

1. Blood Pressure Cuff Dimensions:
   • Inflatable bladder width must be at least 40% of the mid-arm circumference (measured midway between the acromion and olecranon).
   • Inflatable bladder length must encircle 80% to 100% of the mid-arm circumference.
2. Blood Pressure Classification:
   • Stage 2 Hypertension (Hypertensive Emergency): For adolescents $\ge 13$ years of age, Stage 2 hypertension is defined as systolic or diastolic blood pressure $\ge 140/90\text{ mm Hg}$ (or $\ge 95\text{th percentile} + 12\text{ mm Hg}$).
   • Because acute, life-threatening target-organ injury is present (dilated cardiomyopathy, congestive cardiac failure, retinopathy), this is classified as a Hypertensive Emergency.
3. EULAR/PRINTO/PRES Classification Criteria for Childhood Takayasu Arteritis:
   • Mandatory Criterion: Angiographic abnormalities (conventional, CT, or MR angiography) demonstrating focal or diffuse luminal abnormalities, narrowing, or aneurysm of the aorta or its primary branches.
   • Plus $\ge 1$ of the following 4 features:
     • Pulse deficit (diminished/absent pulse) or claudication of an extremity.
     • Blood pressure discrepancy: Systolic blood pressure discrepancy $> 10\text{ mm Hg}$ between any two limbs.
     • Vascular bruits: Audible bruits over the aorta, carotid, subclavian, or femoral vessels.
     • Hypertension: Measured BP $\ge 95\text{th percentile}$ adjusted for age, sex, and height.
4. Pharmacotherapy:
   • Hypertensive Emergency: Intravenous continuous infusion of Labetalol (initial dose 0.25–0.5 mg/kg/hr, titrated up to 1–3 mg/kg/hr; maximum 3 mg/kg/hr) or Sodium Nitroprusside (0.5–2 mcg/kg/min titrated up to 8 mcg/kg/min with arterial line monitoring), aiming for a 25% BP reduction over the first 6–8 hours.
   • Immunosuppression Induction: Pulse intravenous Methylprednisolone: 30 mg/kg/day (maximum 1 g/day) for 3 consecutive days, followed by oral Prednisolone 1–2 mg/kg/day tapering over months.
   • Steroid-sparing Immunosuppressive: Subcutaneous or oral Methotrexate (15 mg/m²/week) or intravenous Cyclophosphamide (500–750 mg/m² monthly pulses for 6 cycles) or biologic therapy (Tocilizumab or Infliximab).

graph TD
    A[Takayasu Arteritis Induced Renovascular / Aortic Stenosis] --> B[Severe Renin-Angiotensin Axis Activation]
    B --> C[Stage 2 Systemic Hypertension]
    C --> D[Left Ventricular Afterload Mismatch]
    D --> E[Cardiomyopathy & Acute Decompensated Heart Failure]
    
    F[Acute Stabilization] --> G[IV Labetalol / Nicardipine / Nitroprusside]
    F --> H[IV Methylprednisolone 30 mg/kg/d x 3 doses]
    H --> I[Steroid-Sparing DMARD / Biologic Induction]

1. Matching Table:
   • Cystinuria: Hexagonal, flat, plate-like crystals (benzene-ring appearance).
   • Tumor lysis syndrome: Diamond, rhomboid, or lemon-shaped crystals (uric acid).
   • Primary hyperoxaluria: Dumbbell or oval-shaped crystals (calcium oxalate monohydrate) and envelope-shaped crystals (calcium oxalate dihydrate).
   • Acyclovir nephrotoxicity: Needle-shaped crystals or birefringent sheaves.
   • Urease-producing UTI: "Coffin-lid" or rectangular prism crystals (triple phosphate / magnesium ammonium phosphate).
2. Urine pH Determinants of Precipitation:
   • Cystine crystals: Acidic urine (precipitates at $\text{pH} < 7.0$; solubility increases dramatically at $\text{pH} > 7.5$).
   • Triple phosphate crystals: Alkaline urine (typically $\text{pH} > 7.2$).
   • Uric acid crystals: Acidic urine (precipitates when $\text{pH} < 5.5$).
3. Diagnostic Testing for Cystinuria:
   • Screening Test: Sodium cyanide-nitroprusside test (Brand's test) on spot urine. Cyanide converts cystine to cysteine; nitroprusside reacts with sulfhydryl groups to produce a vivid cherry-red or purple-magenta coloration.
   • Confirmatory Threshold: 24-hour urinary cystine excretion $> 400\text{ mg/day}$ (or spot urinary cystine $> 250\text{ mg/g creatinine}$).
4. Management Principles for Cystinuria:
   • Hyperhydration: Maintain high fluid intake of $3\text{ L/m}^2/\text{day}$ (including overnight drinking) to keep urinary cystine concentration $< 250\text{ mg/L}$ (1 mmol/L).
   • Urinary Alkalinization: Oral Potassium Citrate ($2\text{ to }4\text{ mEq/kg/day}$ divided into 3–4 doses) titrated to target a urine pH between 7.0 and 7.5.
   • Thiol-Binding / Chelating Agents: Used when hydration and alkalinization fail; D-Penicillamine ($20\text{ to }30\text{ mg/kg/day}$ divided q8h) or Tiopronin ($\alpha$-mercaptopropionylglycine, $15\text{ to }40\text{ mg/kg/day}$).
   • Dietary Modification: Dietary sodium restriction ($< 2\text{ mEq/kg/day}$) and moderate animal protein restriction to decrease renal cystine excretion.

1. Crystal and Calculus Identification:
   • Microscopic Finding: Coffin-lid shaped rectangular prism crystals.
   • Crystal Type: Triple phosphate crystals (Magnesium Ammonium Phosphate hexahydrate / Struvite).
   • Stone Composition: Struvite calculus (Magnesium Ammonium Phosphate combined with Carbonate Apatite).
2. Enzymatic Pathophysiology & Organisms:
   • Pathophysiology: Infection by urease-producing bacteria hydrolyzes urinary urea into ammonia and carbamate:
     $$\text{CO(NH}_2\text{)}_2 + \text{H}_2\text{O} \xrightarrow{\text{Urease}} 2\text{NH}_3 + \text{CO}_2$$
     Ammonia buffers hydrogen ions to form ammonium ($\text{NH}_4^+$), alkalinizing the urine ($\text{pH} > 7.5\text{–}8.0$). Alkaline conditions dissociate phosphate into trivalent phosphate ($\text{PO}_4^{3-}$), which precipitates with magnesium and ammonium to form struvite crystals.
   • Causative Urease-Producing Microorganisms:
     • Proteus mirabilis (most common)
     • Klebsiella pneumoniae
     • Pseudomonas aeruginosa (or Staphylococcus saprophyticus, Serratia marcescens)
3. Dipstick Hematuria Chemistry & False Positives:
   • Biochemical Principle: Pseudoperoxidase activity of the heme moiety of hemoglobin or myoglobin catalyzes the oxidation of an indicator chromogen (e.g., tetramethylbenzidine) by an organic peroxide, producing a color change from yellow to dark green/blue.
   • False-Positive Causes:
     • Myoglobinuria (secondary to rhabdomyolysis).
     • Free intravascular hemoglobinuria (severe hemolytic crisis).
     • Contamination with strong oxidizing agents (hypochlorite/bleach or povidone-iodine).
     • High bacterial peroxidases from heavy urinary tract infection.
4. Metabolic Stone Evaluation Workup:
   • Serum evaluation: Calcium, phosphate, alkaline phosphatase, creatinine, BUN, electrolytes, uric acid, and intact parathyroid hormone (iPTH).
   • 24-hour urine collection (or age-appropriate spot urine-to-creatinine ratios):
     • Calcium
     • Oxalate
     • Uric acid
     • Citrate
     • Cystine
     • Magnesium, Sodium, and Volume
   • Stone composition analysis via Fourier-transform infrared (FTIR) spectroscopy or X-ray powder diffraction on recovered stone fragments.

1. Reflux Grading:
   • Grade IV Vesicoureteral Reflux (VUR).
   • Characterized by moderate dilatation and tortuosity of the right ureter, moderate dilatation of the renal pelvis and calyces, complete blunting of the fornices, but with preservation of the majority of papillary impressions.
2. Indications for Continuous Antibiotic Prophylaxis (CAP):
   • Infants and young children ($< 1\text{ year}$) with high-grade reflux (Grades III to V), irrespective of infection history.
   • Children of any age with recurrent febrile urinary tract infections (breakthrough UTIs) in the presence of VUR.
   • Children with VUR combined with Bowel and Bladder Dysfunction (BBD) / dysfunctional elimination syndrome.
   • Any child with documented renal parenchymal scarring (photopenic defect on DMSA) associated with VUR.
3. Oral Chemoprophylaxis Regimens:
   • Co-trimoxazole (Trimethoprim-Sulfamethoxazole):
     • Dose: $2\text{ mg/kg/day}$ of Trimethoprim component (with $10\text{ mg/kg/day}$ Sulfamethoxazole).
     • Frequency/Timing: Orally, once daily at bedtime.
   • Alternative: Nitrofurantoin:
     • Dose: $1\text{ to }2\text{ mg/kg/day}$.
     • Frequency/Timing: Orally, once daily at bedtime (contraindicated in infants $< 3\text{ months}$ or patients with significant GFR impairment).
4. Indications for Surgical / Endoscopic Intervention:
   • Breakthrough febrile UTIs despite compliant continuous antibiotic prophylaxis.
   • Development of new parenchymal scars or worsening split renal function on serial DMSA scintigraphy.
   • Failure of spontaneous resolution in persistent high-grade VUR (Grade IV–V) in children $> 2\text{ to }3\text{ years}$ of age.
   • Intolerance, severe adverse drug reactions, or parental non-compliance with long-term antibiotic prophylaxis.
   • VUR associated with anatomic obstruction (e.g., duplicated collecting system with ectopic ureterocele or Hutch diverticulum).

graph TD
    A[Infant with Febrile UTI] --> B[Confirm by Catheterized Urine Culture]
    B --> C[Renal Bladder Ultrasound]
    C --> D[Voiding Cystourethrogram - VCUG]
    D --> E{VCUG Result}
    E -->|Grade I-II| F[Surveillance +/- CAP if recurrent/BBD]
    E -->|Grade III-V| G[Continuous Antibiotic Prophylaxis - CAP]
    G --> H[DMSA Renal Scan at 3-6 Months post-UTI]
    H --> I{Breakthrough UTI or New Scars?}
    I -->|Yes| J[Endoscopic Deflux or Ureteral Reimplantation]
    I -->|No| K[Continue CAP & Serial Surveillance]